In the Era of Precision Medicine, the Importance of Pathological Diagnosis is Highlighted—Latest “Clinical Rational Use Management Indicators for Antitumor Drugs” Released

In principle, only malignant tumors confirmed by tissue or cytological pathological diagnosis or established by special molecular pathological testing have indications for the use of antineoplastic drugs and targeted therapies. Cancer patients diagnosed solely based on clinical symptoms, signs, and imaging results without pathological confirmation have no indication for the use of antineoplastic drugs and targeted therapies;

For certain tumors where pathological diagnosis is difficult to obtain, such as pancreatic cancer, the diagnosis can be made with reference to relevant national guidelines or standards;

For antineoplastic targeted drugs with clear targets, corresponding target testing must be performed before use;

Pathological reports should be credible and must be issued by medical institutions with appropriate qualifications, including pathological diagnosis and testing reports or pathological consultation reports;

The denominator is the number of patients initially treated with antineoplastic drugs and targeted therapies.